Page 12 - Boxed Warning News Today

The FDA has approved Casgevy and Lyfgenia, the first cell-based gene therapies for the treatment of sickle cell disease in patients 12 years of age and older.

The FDA has approved Casgevy and Lyfgenia, the first cell-based gene therapies for the treatment of sickle cell disease in patients 12 years of age and older.

Separate decisions by federal district courts in Texas and Puerto Rico in the past two months provide cautionary tales for every pharmacy and wholesale distributor dispensing...

/PRNewswire/ -- Marius Pharmaceuticals, a pharmaceutical company focused on developing innovative therapies for testosterone deficiency, today announces the...

New FDA-approved label updates offer patients more flexible administrationPARSIPPANY, N.J.--(BUSINESS WIRE)--The U.S. Food and Drug Administration (FDA) has approved two new changes to the label of Tirosint-SOL (levothyroxine sodium) oral solution, a unique formulation of levothyroxine (LT4) for the treatment of hyp...

Expert dermatologists review the safety data of the current JAK inhibitors approved for AD, highlighting adverse events and long-term safety data.

Zepbound (tirzepatide) is now available for chronic weight management in adults who are obese or overweight with a comorbidity.

Study presents new persistence analysis of FINTEPLA, evaluating the efficacy and tolerability of FINTEPLA over a span of 12 months1 Real-world data looks into the need for resources to support caregivers – both parents and siblings – of people living with developmental and epileptic encephalopathies such as Dravet and Lennox-Gastaut syndromes in the transition from […]

Proposed acquisition will accelerate AbbVies entry into the commercial market for ovarian cancer ELAHERE® is a first-in-class antibody-drug conjugate (ADC)...

UCB will present 29 abstracts, including 4 late breakers, at American Epilepsy Society Annual Meeting 2023 highlighting clinical, health economic and...